Encompass Health (EHC) stock is in focus after first quarter 2026 results topped Wall Street expectations, management raised full year revenue and adjusted EPS guidance, and the company continued expanding its inpatient rehabilitation hospital network.

The recent 1 day share price return of 2.0% to $107.15 and 7 day share price return of 7.2% suggest momentum has picked up following the earnings beat, higher guidance, new hospital opening and ongoing dividends, even though the 1 year total shareholder return is a 6.9% decline compared with 3 year and 5 year total shareholder returns of 77.1% and 61.5% respectively.

If this earnings driven move has you reassessing your watchlist, it can help to widen the lens beyond a single stock and check out 35 healthcare AI stocks

With Encompass Health trading at $107.15 and data pointing to both an implied discount to analyst targets and intrinsic value estimates, investors now face a key question: is there still an opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 8% Overvalued

At $107.15, Encompass Health sits above the narrative fair value of $99.17, which frames the current move against a thesis focused on outcome centric rehabilitation.

EHC has demonstrated consistent revenue growth and disciplined expansion through new hospital openings and occupancy improvements. The company benefits from demographic tailwinds, including an aging population and rising demand for post-acute rehabilitation services. Yet what may matter more long term is how effectively providers adapt to outcome-based healthcare frameworks.

The narrative leans heavily on sustained earnings power, margin resilience and a valuation multiple that assumes outcome based care keeps strengthening the inpatient rehab model. It is worth examining which assumptions do the most heavy lifting in this view.

Result: Fair Value of $99.17 (OVERVALUED)

However, this story can be challenged if outcome based reimbursement shifts or if inpatient rehab faces tougher competition and cost pressures that squeeze margins.

Another View: Earnings And Cash Flow Point To Upside

The 8% premium to the narrative fair value contrasts with our DCF model, which suggests that Encompass Health at $107.15 is trading at a 36% discount to an estimated future cash flow value of $167.49. This raises the question of which story carries more weight: sentiment or cash generation.

Next Steps

With sentiment clearly split between risk and reward, do not wait around for a consensus that may never come. Weigh the positives and negatives yourself, then stress test your view against the 5 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Encompass Health has sharpened your focus, do not stop here. Put the same scrutiny to work across other stocks so potential opportunities do not pass you by.

• Target quality at a discount by checking stocks that screen well on valuation and fundamentals through the 51 high quality undervalued stocks.
• Prioritise resilience and sleep better at night by scanning companies that clear tough balance sheet checks with the solid balance sheet and fundamentals stocks screener (44 results).
• Get ahead of the crowd by reviewing stronger fundamentals hidden in the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.